Actinium Pharmaceuticals
Stock Forecast, Prediction & Price Target
Actinium Pharmaceuticals Financial Estimates
Actinium Pharmaceuticals Revenue Estimates
Actinium Pharmaceuticals EBITDA Estimates
Actinium Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $1.14M N/A | $1.03M -9.96% | $81K -92.13% | Avg: $57.03M Low: $30.42M High: $83.63M avg. 70309.56% | Avg: $130.40M Low: $68.29M High: $226.43M avg. 128.65% | Avg: $257.12M Low: $134.65M High: $446.46M avg. 97.16% | Avg: $398.24M Low: $208.56M High: $691.50M avg. 54.88% |
Net Income
% change YoY
| $-24.58M N/A | $-31.93M -29.88% | $-48.81M -52.89% | Avg: $-14.96M Low: $-54.80M High: $32.19M avg. 69.34% | Avg: $39.66M Low: $-36.18M High: $109.07M avg. 365.09% | Avg: $77.20M Low: $29.40M High: $151.11M avg. 94.61% | Avg: $137.48M Low: $52.35M High: $269.10M avg. 78.08% |
EBITDA
% change YoY
| $-24.44M N/A | $-33.40M -36.68% | $-51.13M -53.06% | Avg: $-11.40M Low: $-16.72M High: $-6.08M avg. 77.69% | Avg: $-26.08M Low: $-45.28M High: $-13.65M avg. -128.65% | Avg: $-51.42M Low: $-89.29M High: $-26.93M avg. -97.16% | Avg: $-79.64M Low: $-138.30M High: $-41.71M avg. -54.88% |
EPS
% change YoY
| -$1.2 N/A | -$1.32 -10.00% | -$1.83 -38.63% | Avg: -$0.45 Low: -$2.06 High: $1.21 avg. 75.14% | Avg: $1.05 Low: -$1.36 High: $4.1 avg. 331.27% | Avg: $2.9 Low: $1.11 High: $5.68 avg. 175.85% | Avg: $5.17 Low: $1.97 High: $10.12 avg. 78.08% |
Operating Expenses
% change YoY
| $26.10M N/A | $35.13M 34.57% | $52.00M 48.00% | Avg: $2.11B Low: $1.12B High: $3.09B avg. 3964.31% | Avg: $4.83B Low: $2.53B High: $8.39B avg. 128.65% | Avg: $9.52B Low: $4.99B High: $16.54B avg. 97.16% | Avg: $14.75B Low: $7.72B High: $25.62B avg. 54.88% |
FAQ
What is Actinium Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 151.78% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -54.80M, average is -14.96M and high is 32.19M.
What is Actinium Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 17647.56% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $30.42M, average is $57.03M and high is $83.63M.
What is Actinium Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 165.09% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$2.06, average is -$0.45 and high is $1.21.
What is the best performing analyst?
In the last twelve months analysts have been covering Actinium Pharmaceuticals stock. The most successful analyst is Sudan Loganathan.